Xencor, Inc. (NASDAQ:XNCR) Receives $24.50 Consensus Target Price from Analysts

Xencor, Inc. (NASDAQ:XNCR) has been given an average recommendation of “Hold” by the ten brokerages that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $24.50.

XNCR has been the subject of several analyst reports. JPMorgan Chase & Co. boosted their target price on shares of Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Monday, May 11th. Zacks Research cut shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Wall Street Zen cut shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Barclays upped their price objective on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research report on Friday, March 27th.

Insiders Place Their Bets

In other Xencor news, VP John R. Desjarlais sold 4,118 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $11.25, for a total transaction of $46,327.50. Following the completion of the transaction, the vice president directly owned 266,333 shares in the company, valued at approximately $2,996,246.25. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Celia Eckert sold 3,244 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $11.25, for a total transaction of $36,495.00. Following the transaction, the senior vice president owned 78,685 shares of the company’s stock, valued at $885,206.25. This represents a 3.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 44,020 shares of company stock worth $499,817. Company insiders own 4.76% of the company’s stock.

Hedge Funds Weigh In On Xencor

A number of large investors have recently added to or reduced their stakes in the stock. BVF Inc. IL grew its holdings in shares of Xencor by 160.3% during the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after buying an additional 4,393,579 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Xencor by 603.7% during the third quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock worth $14,932,000 after buying an additional 1,092,095 shares in the last quarter. State Street Corp grew its holdings in shares of Xencor by 22.7% during the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock worth $69,006,000 after buying an additional 833,423 shares in the last quarter. Jefferies Financial Group Inc. grew its holdings in shares of Xencor by 620.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock worth $11,030,000 after buying an additional 620,440 shares in the last quarter. Finally, RTW Investments LP grew its holdings in shares of Xencor by 8.9% during the fourth quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock worth $103,763,000 after buying an additional 556,407 shares in the last quarter.

Xencor Trading Down 0.8%

Shares of NASDAQ XNCR opened at $11.88 on Friday. The company has a 50 day simple moving average of $12.17 and a two-hundred day simple moving average of $13.34. Xencor has a 12 month low of $6.92 and a 12 month high of $18.69. The stock has a market cap of $880.78 million, a price-to-earnings ratio of -5.19 and a beta of 0.93.

Xencor (NASDAQ:XNCR) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.96). Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The firm had revenue of $4.52 million during the quarter, compared to analyst estimates of $27.86 million. During the same quarter in the prior year, the firm earned ($0.66) earnings per share. The business’s revenue for the quarter was down 86.2% on a year-over-year basis. Analysts forecast that Xencor will post -3.82 EPS for the current year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.